

Matteo Toma, MD, FISC

CURRICULUM VITAE

PERSONAL INFORMATION

<i>Name</i>	Matteo Toma
<i>Date of birth</i>	
<i>Nationality</i>	Italian
<i>Work address</i>	Cardiovascular Disease Unit IRCCS Policlinico San Martino L.go Rosanna Benzi, 10 16132, Genova (GE), Italy

CURRENT APPOINTMENT

<i>October, 17th 2022 - ongoing</i>	Consultant Cardiologist Cardiovascular Disease Unit Cardio-Thoracic-Vascular Department IRCCS Policlinico San Martino Genova (GE), Italy
--	--

PREVIOUS APPOINTMENT

<i>April, 16th 2021 – April, 15th 2022</i>	Research fellowship for the project: “Coronary Physiology Testing in Acute Coronary Syndromes (CoPhyTea)” Cardiovascular Disease Unit Cardio-Thoracic-Vascular Department IRCCS Policlinico San Martino Genova (GE), Italy
--	---

EDUCATION

<i>November 2020</i>	European Association of Cardiovascular Imaging Adult Transthoracic Echocardiography Certification
<i>November 2016 –</i>	Residency in Cardiology

<i>November 2020</i>	Cardiovascular Disease Unit, Cardio-Thoracic-Vascular Department, IRCCS Policlinico San Martino, Genova and Department of Internal Medicine, University of Genova
<i>February 2016</i>	Italian Medical License University of Turin
<i>2008 – 2015</i>	School of Medicine University of Turin

MEMBERSHIP OF SCIENTIFIC SOCIETIES

<i>2021 – ongoing</i>	ESC Working Group on Pulmonary Circulation & Right Ventricular Function
<i>2020 - ongoing</i>	Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO)
<i>2019 – ongoing</i>	European Society of Cardiology (ESC), Professional Member
<i>2019 - 2020</i>	European Association of Cardiovascular Imaging (EACVI), Silver Member
<i>2019 - ongoing</i>	Heart Failure Association (ESC - HFA)
<i>2019 - ongoing</i>	Heart Failure Specialists of Tomorrow (ESC - HoT)
<i>2019 - ongoing</i>	Associazione Regionale Cardiologi Ambulatoriali - Liguria (ARCA)
<i>2018 - ongoing</i>	Società Italiana di Cardiologia (SIC) Fellow for Italian Society of Cardiology since 2020 Consigliere Sezione SIC Liguria Triennio 2023 - 2025

SCIENTIFIC ACTIVITY

Scopus h-index: 8

Web of Science h-index: 8

AUTHOR OF THE FOLLOWING PAPERS PUBLISHED IN PEER-REVIEWED JOURNALS

1. **Toma M**, Savonitto G, Lombardi CM, Airò E, Driussi M, Gentile P, Howard L, Moschella M, Di Poi E, Pagnesi M, Monti S, Collini V, D'Angelo L, Vecchiato V, Giannoni A, Adamo M, Barbisan D, Bauleo C, Garascia A, Metra M, Sinagra G, Lo Giudice F, Stolfo D, Ameri P. Frequency, characteristics and risk assessment of pulmonary arterial hypertension with a left heart disease phenotype. Clin Res Cardiol. 2024 Apr 15. doi: 10.1007/s00392-024-02448-9

2. Phenotype and Outcomes According to Loop Diuretic Use in Pulmonary Arterial Hypertension. Savonitto G, Barbisan D, Ameri P, Lombardi CM, Monti S, Driussi M, Gentile P, Howard L, **Toma M**, Pagnesi M, Collini V, Bauleo C, Adamo M, D'Angelo L, Nalli C, Giannoni A, Vecchiato V, Di Poi, E, Airo E, Metra M, Garascia A, Sinagra G, Lo Giudice F, Stolfo D. ESC HF (2024). doi: 10.1002/ehf2.14818
3. Tini G, Tanda S, **Toma M**, Battistoni A, Musumeci B, Barbato E, Canepa M, Ameri P. Guideline-Directed Medical Therapy in Patients With Heart Failure With Reduced Ejection Fraction and Incident Cancer. Heart Lung Circ. 2024 Apr 11:S1443-9506(24)00169-0. doi: 10.1016/j.hlc.2024.03.008
4. Masini M*, **Toma M***, Spallarossa P, Porto I, Ameri P. Direct Oral Anticoagulants for Cancer - Associated Venous Thromboembolism. Curr Oncol Rep. 2023 Sep;25(9):979-987. doi: 10.1007/s11912-023-01428-y (*equally contributed)
5. Bertero E, Fracasso G, Eustachi V, Coviello D, Cecconi M, Giovinazzo S, **Toma M**, Merlo M, Sinagra G, Porto I, Ameri P, Canepa M. Diagnostic yield and predictive value on left ventricular reverse remodeling of genetic testing in dilated cardiomyopathy. ESC Heart Fail. 2023 Aug;10(4):2745-2750. doi: 10.1002/ehf2.14395.
6. Stolfo D, Barbisan D, Ameri P, Lombardi CM, Monti S, Driussi M, Zovatto IC, Gentile P, Howard L, **Toma M**, Pagnesi M, Collini V, Bauleo C, Guglielmi G, Adamo M, D'Angelo L, Nalli C, Sciarrone P, Moschella M, Zorzi B, Vecchiato V, Milani M, Di Poi E, Airo E, Metra M, Garascia A, Sinagra G, Lo Giudice F. Performance of risk stratification scores and role of comorbidities in older vs younger patients with pulmonary arterial hypertension. J Heart Lung Transplant. 2023 Mar 5:S1053-2498(23)01773-4. doi: 10.1016/j.healun.2023.02.1707
7. **Toma M**, Miceli R, Bonsante E, Colombo D, Confalonieri M, Garascia A, Ghio S, Lattanzio M, Lombardi CM, Paciocco G, Piccinino C, Rota I, Santolamazza C, Scelsi L, Scuri P, Stolfo D, Vincenzi A, Volpiano L, Vicenzi M, Ameri P. Left Heart Disease Phenotype in Elderly Patients with Pulmonary Arterial Hypertension: Insights from the Italian PATRIARCA Registry. J. Clin Med. 2022, 11, 7136. doi: 10.3390/jcm11237136
8. Badagliacca R, Papa S, D'Alto M, Ghio S, Agostoni P, Ameri P, Argiento P, Brunetti ND, Casamassima V, Casu G, Cedrone N, Confalonieri M, Corda M, Correale M, D'Agostino C, De Michele L, Famoso G, Galgano G, Greco A, Lombardi C, Manzi G, Madonna R, Mercurio V, Mulè M, Paciocco G, Romaniello A, Romeo E, Scelsi L, Serra W, Stolfo D, **Toma M**, Vatrano M, Vitulo P, Vizza CD. The paradox of pulmonary arterial hypertension

- in Italy in the COVID-19 era: is risk of disease progression around the corner? *Eur Respir J*. 2022 Oct 6;60(4):2102276. Doi: 10.1183/13993003.02276-2021.
9. **Toma M**, Guglielmi G, Crimi G, Porto I, Ameri P. Risk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. *Outpatient Cardiology* 2021, 2:123-130. doi: 10.17473/1971-6818-2021-2-5
 10. Giovinazzo S, Carmisciano L, **Toma M**, Benenati S, Tomasoni D, Sormani MP, Porto I, Canepa M, Senni M, Metra M, Ameri P. Sacubitril-valsartan in real-life European patients with heart failure and reduced ejection fraction. *ESC Heart Fail* 2021 Oct;8(5):3547-3556. doi: 10.1002/ehf2.13547
 11. **Toma M**, Giovinazzo S, Crimi G, Masoero G, Balbi M, Montecucco F, Canepa M, Porto I, Ameri P. Multi-parametric vs. inferior vena cava-based estimation of right atrial pressure. *Front. Cardiovasc. Med.* 8:632302. doi: 10.3389/fcvm.2021.632302.
 12. Menichelli D, Vicario T, Ameri P, **Toma M**, Violi F, Pignatelli P, Pastori D. Cancer and atrial fibrillation: Epidemiology, mechanisms and anticoagulation treatment. Doi: 10.1016/j.pcad.2021.04.004.
 13. Benenati S, **Toma M**, Canale C, Vergallo R, Della Bona R, Ricci D, Canepa M, Crimi G, Santini F, Ameri P, Porto I. Mechanical circulatory support in patients with cardiogenic shock not secondary to cardiectomy: a network meta-analysis. *Heart Fail Rev.* 2021 Mar 6. doi: 10.1007/s10741-021-10092-y.
 14. **Toma M**, Rrapaj E, Spallarossa P, Guerra F, Ameri P. Patterns of anticoagulation for atrial fibrillation in cancer patients referred to cardio-oncological evaluation. *Eur J Intern Med.* 2020 Aug 5;S0953-6205(20)30319-8. doi: 10.1016/j.ejim.2020.08.004.
 15. Spallarossa P, Sarocchi M, Tini Melato G, Arboscello E, **Toma M**, Ameri P, Porto I. How to Monitor Cardiac Complications of Immune Checkpoint Inhibitor Therapy. *Front. Pharmacol.* 11:972. doi: 10.3389/fphar.2020.00972.
 16. Ameri P, Riva L, **Toma M**, Di Pasquale G, De Caterina R. One-year follow-up of Italian patients with atrial fibrillation treated with edoxaban in ETNA-AF Europe. *G Ital Cardiol* 2020;21(7):546-557. doi: 10.1714/3386.33644.
 17. Benenati S, Galli M, De Marzo V, Pescetelli F, **Toma M**, Andreotti F, Della Bona R, Canepa M, Ameri P, Crea F, Porto I. Very Short vs. Long Dual Antiplatelet Therapy after Second Generation Drug-eluting Stents in 35,785 Patients undergoing Percutaneous Coronary Interventions: a Meta-analysis of Randomised Controlled Trials. *Eur Heart J Cardiovasc Pharmacother.* 2020 Jan 14. pii: pvaa001. doi: 10.1093/ehjcvp/pvaa001.

AUTHOR OF THE FOLLOWING BOOK CHAPTER

- **Toma M**, Ameri P, Porto I. Scopenso Cardiaco: dalla fisiopatologia alle strategie terapeutiche. La diagnosi strumentale invasiva. (2023) p. 81-88. Infodyn edizioni.

INVESTIGATOR IN SEVERAL MULTI-CENTER RANDOMIZED CLINICAL TRIALS AND OBSERVATIONAL STUDIES:

<i>2024 - ongoing</i>	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Inhalation of Seralutinib for the Treatment of Pulmonary Arterial Hypertension.
<i>2024 - ongoing</i>	A phase IIb Study of AZD3427 in Participants with Heart Failure and Pulmonary Hypertension Group 2 (RE-PHIRE).
<i>2023 - ongoing</i>	Primary Unloading and Delayed Reperfusion in ST-Elevation Myocardial Infarction: The STEMI DTU Trial.
<i>2024 - ongoing</i>	Sub-investigator in Randomised, double-blind, placebo-controlled study to investigate a single administration of BI 765845 on top of standard of care in patients with acute myocardial infarction (Boehringer Ingelheim trial No 1478-0002)
<i>2023 - ongoing</i>	Sub-investigator in Effects of ziltivekimab versus placebo on morbidity and mortality in patients with heart failure with mildly reduced or preserved ejection fraction and systemic inflammation (HERMES trial)
<i>2021 - 2024</i>	Sub-investigator in non-INterventional Study on Pulmonary artERial hypertension patients treated with maCiTentan and/or selexipag: experience from an Italian cOhort (INSPECTIO, Protocol 67896049PAH4009).
<i>2021 - 2023</i>	Sub-investigator in Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Rodatristat Ethyl in Patients with Pulmonary Arterial Hypertension (ELEVATE-2), RVT-1201-2002, Altavant Sciences GmbH.
<i>2020 - 2022</i>	Sub-investigator and Study Coordinator in Coronary Physiology Testing in Acute Coronary Syndromes (CoPhyTeA).
<i>2020 - ongoing</i>	Sub-investigator and Study Coordinator in A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients (ROR-PH-301, ROR-PH-303; NCT03626688).
<i>2019 - ongoing</i>	Sub-investigator in EXPOSURE: Post-authorisation safety study

	(PASS): observational cohort study of PAH patients newly treated with either Uptravi® (selexipag) or any other PAH-specific therapy, in clinical practice. [<i>Certificate of excellence for the contribution within the study</i>].
2019 - 2022	Sub-investigator in: An Italian multicenter prospective study on Pulmonary Hypertension modality of death and validation of Reveal risk score (Aspyre-1 Study).
2019 - 2022	Sub-investigator in BLITZ-AF Cancer Study. [<i>Global top enroller centre</i>].
2019 - 2020	Sub-investigator in The global Edoxaban Treatment in routine clinical practice (ETNA-AF) noninterventional study program.
2017	Sub-investigator in A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients (MARINER, NCT02111564).

SELECTED ABSTRACTS AT NATIONAL OR INTERNATIONAL CONGRESSES

2023	84° Congresso Nazionale Società Italiana di Cardiologia (Roma) Use of PAH-SYMPACT questionnaire in real-life. V. Vecchiato, M. Toma , B. Matilde, S. Tanda, M. Solimano, M. Licausi, G. Guglielmi, I. Porto, P. Ameri
2023	European Society of Cardiology Congress (Amsterdam), Oral session Risk assessment according to the presence of left heart disease phenotype in pulmonary arterial hypertension patients: a multicenter cohort study. M. Toma , D. Barbisan, CM. Lombardi, E. Airo, M. Driussi, P. Gentile, L. Howard, M. Moschella, E. Di Poi, A. Garascia, M. Adamo, G. Sinagra, F. Lo Giudice, D. Stolfo, P. Ameri.
2022	83° Congresso Nazionale Società Italiana di Cardiologia (Roma) NTproBNP across PH groups P. Costa, M. Solimano, G. Crimi, M. Vercellino, A. Macchione, M. Toma , I. Porto, P. Ameri
2022	83° Congresso Nazionale Società Italiana di Cardiologia

2021

(Roma)

Hyperkalemia, use of drugs targeting the renin-angiotensin-aldosterone system and mortality in patients followed at a tertiary center.

A. Bernardelli, S. Mori, **M. Toma**, V. Vecchiato, E. Bertero, T. Semino, G. Di Pietro, S. Giovinazzo, I. Porto, M. Canepa, P. Ameri

82° Congresso Nazionale Società Italiana di Cardiologia (Roma), Special abstract session

Left heart disease phenotype and use of pulmonary vasodilators in elderly patients with pulmonary Arterial Hypertension: The PATRIARCA registry

M. Toma, R. Miceli, E. Bonsante, M. Confalonieri, A. Garascia, S. Ghio, M. Lattanzio, CM. Lombardi, G. Paciocco, C. Piccinino, I. Rota, L. Scelsi, P. Scuri, D. Stolfo, A. Vincenzi, M. Vicenzi. P. Ameri

European Heart Journal Supplements, Volume 23, Issue Supplement_G, December 2021, suab133.026. doi: 10.1093/eurheartj/suab133.026

2020

81° Congresso Nazionale Società Italiana di Cardiologia (Digital), Oral session

Factors dictating the decision to proceed with right heart catheterization after a visit for pulmonary hypertension: the importance of proper referral

A. Bernardelli*, **M. Toma***, G. Fracasso, F. Scanavino, R. Miceli, I. Porto, P. Ameri (*equally contributed)

European Heart Journal Supplements (2020) 22 (Supplement N), N88-N102. doi: 10.1093/eurheartj/suaa202

2020

European Society of Cardiology Congress (Digital), ePoster
Patterns of anticoagulation for atrial fibrillation in cancer patients referred for cardio-oncological evaluation.

M. Toma, E. Rrapaj, S. Giovinazzo, M. Sarocchi, G. Stronati, A. Dello Russo, I. Porto, P. Spallarossa, F. Guerra, P. Ameri
European Heart Journal, Volume 41, Issue Supplement 2,

- November 2020, ehaa946.3269,
<https://doi.org/10.1093/ehjci/ehaa946.3269>
- 2020 European Society of Cardiology Congress (Digital), ePoster
 Sacubitril/valsartan in real-life European patients with heart failure with reduced ejection fraction: a systematic review and meta-analysis.
 S. Giovinazzo, L. Carmisciano, **M. Toma**, MP. Sormani, M. Canepa, M Senni, I Porto, P. Ameri
 European Heart Journal, Volume 41, Issue Supplement_2, November 2020, ehaa946.1028,
<https://doi.org/10.1093/ehjci/ehaa946.1028>
- 2020 Heart Failure Association (Digital), Presentation
 Inferior vena cava-based vs multi-parametric estimation of right atrial pressure by echocardiography.
M. Toma, S. Giovinazzo, D. Sirello, F. Scanavino, G. Fracasso, R. Miceli, M. Canepa, I. Porto, P. Ameri
- 2019 80° Congresso Nazionale Società Italiana di Cardiologia (Roma), Poster
 Features of heart failure with mid-range vs. reduced or preserved left ventricular ejection fraction.
M. Toma, S. Giovinazzo, G. Rizzola, G. La Malfa, I. Porto, M. Canepa, P. Ameri
- 2019 80° Congresso Nazionale Società Italiana di Cardiologia (Roma), Poster
 Characteristics and outcomes of heart failure patients with a history of cancer.
 S. Giovinazzo, **M. Toma**, G. La Malfa, G. Rizzola, V. De Marzo, A. Tirandi, I. Porto, M. Canepa, P. Ameri
 European Heart Journal Supplements (2019) 21 (Supplement J), J120–J145. doi: 10.1093/eurheartj/suz259
- 2019 European Society of Cardiology Congress (Paris), Oral session
 Myopericarditis complicating meningococcal sepsis.
M. Toma, S. Giovinazzo, R. Miceli, A. Della Vecchia, G.

2019

Buscaglia, A. Gratarola, L.A. Nicolini, I. Porto, P. Ameri.
Heart Failure Associations Congress (Athens), Poster
Longitudinal changes in serum creatinine in patients with
heart failure receiving oral anticoagulation for atrial
fibrillation.
S. Giovinazzo, **M. Toma**, G. Ghigliotti, F. Chiarella, C.
Brunelli, I. Porto, M. Canepa, P. Ameri.

2018

79° Congresso Nazionale Società Italiana di Cardiologia
(Roma)
Oral session
Thrombin induces Protease-Activated Receptor 1 signaling
and activation of human atrial fibroblasts and dabigatran
prevents these effects.
M. Toma, P. Altieri, M. Bertolotto, P. Fabbi, E. Sportelli, M.
Balbi, F. Santini, M. Canepa, F. Montecucco, C. Brunelli, P.
Ameri

AWARDS

2021

Winner for best abstract at 82° Congresso Nazionale Società Italiana di
Cardiologia (Roma).

2019

Winner for the best clinical case at 80° Congresso Nazionale Società
Italiana di Cardiologia (Roma).

2019

Winner for the best abstract at ARCA YOUNG (Liguria). Title
“Assessment of Right atrial funCtion to predict Adverse outcomes in
Pulmonary Hypertension (ARCA-PH study).”

MEMBER OF THE SCIENTIFIC COMMITTEE OF THE FOLLOWING CONGRESSES

10/11/2023

IPER-LIGURIA: diagnosi e terapia dell’ipertensione polmonare in
Liguria.

FACULTY AND INVITED SPEAKER AT THE FOLLOWING CONGRESSES

13/06/2024

PLACE (vd acronimo in email)

10/06/2024

Ipertensione polmonare nel ponente ligure

20/04/2024

A.R.C.A. Liguria

<i>27/05/2023</i>	Il cuore in fortezza (Savona)
<i>26/05/2023</i>	FOCUS ON CARDIO-PNEUMO-REUMATOLOGIA “Percorsi condivisi e Condivisibili di Malattia” (Genova)
<i>13/04/2023</i>	Ipertensione Polmonare: Update e percorso organizzativo nel ponente ligure (Savona)
<i>15/11/2022</i>	Approccio multidisciplinare all’ipertensione polmonare nelle malattie autoimmuni reumatiche.
<i>11/11/2022</i>	Arca Eco: Ipertensione Polmonare
<i>07/10/2022</i>	Iper-Liguria: diagnosi e terapia dell’ipertensione polmonare in Liguria (Genova)
<i>28/05/2022</i>	alpha events: Ipertensione Arteriosa Polmonare dall’alpha all’omega
<i>29/10/2021</i>	Fibrillazione atriale: Now Next Generation (Camogli)
<i>17/09/2021</i>	Ipertensione polmonare: percorsi di collaborazione e rete regionale Ligure. (Genova)
<i>18/05/2021</i>	La gestione della terapia per la PAH dalle evidenze scientifiche alla pratica clinica. Il ruolo degli stimolatori della Guanilato Ciclastasi Solubile: esperienze a confronto
<i>10/04/2021</i>	A.R.C.A. Liguria Web edition
<i>2020 - 2021</i>	Tutorship PAH Liguria: progetto educativo per favorire la diagnosi precoce dell’ipertensione arteriosa polmonare e favorire l’integrazione ospedale-territorio.
<i>28/11/2020</i>	21° Congresso Nazionale A.R.C.A.
<i>24/11/2020</i>	ARCA ECG
<i>29/09/2020</i>	Cuore e vaccini (Genova)
<i>05/09/2020</i>	Aggiornamento sulle cardiotossicità dei nuovi antitumorali. Focus su carcinoma polmonare e melanoma. (Genova)
<i>15/12/2019</i>	80° Congresso Nazionale Società Italiana di Cardiologia (Roma)
<i>28/02/2019</i>	Cardio-imaging: Focus Malattie del Pericardio (Savona)
<i>23/11/2018</i>	Heartline (Genova)

As of May, 18th 2024.
